Immuron to Cooperate with Leading Australian Universities on Autism Research
July 20, 2016 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 20, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company, Immuron Limited (ASX:IMC) (OTCQB:IMROY), today announced it has formed a strategic...
Immuron Rights Issue Raises $5.33M
July 07, 2016 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 07, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY), is pleased to announce that the Company has...
Travelan to Reach Up to 1.5M New US Customers via Magellan’s
June 30, 2016 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, June 30, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY) is pleased to announce that Travelan will be...
Immuron Significantly Expands US Distribution Reach with McKesson Agreement
June 29, 2016 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, June 29, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY), today announced that the Company has executed a...
Travelan and Protectyn Are Now Available For Sale in China
June 27, 2016 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, June 27, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY) is pleased to announce that QBID has placed its...
Immuron Announces E-Commerce Agreement with QBID in China
June 24, 2016 08:40 ET
|
Immuron Limited
MELBOURNE, Australia, June 24, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY) today announced it has entered into a distribution...
NASH Phase II Trial Reaches 50% Patient Recruitment Milestone
June 23, 2016 16:05 ET
|
Immuron Limited
MELBOURNE, Australia, June 23, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY) today announced that the Company’s IMM-124E Phase II...
Immuron Signs Shigella Vaccine Development Agreement with US Army
June 23, 2016 09:07 ET
|
Immuron Limited
MELBOURNE, Australia, June 23, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY), is pleased to announce that the Company has...
Immuron Announces Statistically Significant Results of Triple-Action Anti-Infective IMM-529 in Pre-Clinical Clostridium difficile Recurrence Studies
January 12, 2016 11:17 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 12, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY) today announced that IMM-529, a first-in-class oral...
NASH Clinical Trail Surpasses 25% Patient Recruitment Milestone
November 18, 2015 13:57 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Australian biopharmaceutical Company Immuron Limited (ASX:IMC) (OTCQB:IMROY) is pleased to announce that the Company’s Phase IIb, the...